Healthcare experts and government officials have urged pharmaceutical regulators, industries, and academia to work collaboratively in ensuring the production of high-quality healthcare products in Pakistan.

During a national workshop on pharmaceutical advancements, speakers emphasized that 90% of the country’s medicines are now locally produced, with over 700 pharmaceutical manufacturing facilities operating nationwide. This sector has significantly contributed to Pakistan’s economy, accounting for 52% of total exports.

The workshop, titled “The Role of Regulators, Pharma Industry, and Academia in Promoting Quality Healthcare Products,” was jointly organized by the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), University of Karachi, and the Drug Regulatory Authority of Pakistan (DRAP).

Addressing the session, key officials—including Sindh’s Provincial Health Secretary, the Chairman of the Pakistan Pharmaceutical Manufacturers Association (PPMA), and renowned academic figures—underscored the importance of advancing local pharmaceutical production. They stressed the need for a unified platform to bridge government, industry, and academia for enhancing drug development and distribution.

The event highlighted ongoing research efforts, industry growth, and the role of cutting-edge scientific advancements in improving healthcare accessibility. Officials reaffirmed their commitment to supporting local pharmaceutical manufacturers in achieving international quality standards while ensuring essential medicines remain accessible to the public.

With continued investment and collaboration, Pakistan’s pharmaceutical sector aims to solidify its position as a leading industry in South Asia, driving innovation and healthcare improvements for the nation.